T2 Biosystems (NASDAQ:TTOO – Get Free Report) released its earnings results on Monday. The medical equipment provider reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.31, Yahoo Finance reports. The business had revenue of $1.95 million for the quarter. T2 Biosystems updated its FY 2024 guidance to EPS.
T2 Biosystems Stock Performance
Shares of NASDAQ TTOO opened at $4.88 on Thursday. The firm’s 50-day moving average price is $5.10 and its 200-day moving average price is $4.48. T2 Biosystems has a 12-month low of $2.60 and a 12-month high of $70.00.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on TTOO shares. StockNews.com upgraded shares of T2 Biosystems to a “sell” rating in a research note on Tuesday. Canaccord Genuity Group upped their target price on shares of T2 Biosystems from $3.00 to $5.00 and gave the stock a “hold” rating in a report on Tuesday.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
See Also
- Five stocks we like better than T2 Biosystems
- Market Cap Calculator: How to Calculate Market Cap
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
- With Risk Tolerance, One Size Does Not Fit All
- Financial Sector Shines as Key Players Continue to Beat Earnings
- How to Calculate Inflation Rate
- Russell 2000 Index Bull Run: This ETF is Poised for Growth
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
